India, July 6 -- image credit- freepik

Immuneel Therapeutics, Bengaluru-based cell and gene therapy company, has announced a strategic partnership with Arogya Finance to introduce India's first Zero Cost EMI programme of up to Rs 25 lakh for eligible patients undergoing treatment with Qartemi(R) (Varnimcabtagene autoleucel), Immuneel's CD19-directed autologous CAR-T cell therapy.

The collaboration marks a significant milestone in improving patient access to advanced cancer care by addressing one of the most critical barriers to treatment-timely affordability. The partnership has been formalised through a collaboration agreement under which Arogya Finance will independently provide financing to eligible patients, while Immuneel continues...